文献速递临床生化临床免疫

糖尿病心力衰竭筛查中利钠肽应用的挑战:IFCC C-CB报告

Challenges of using natriuretic peptides to screen for the risk of developing heart failure in patients with diabetes: a report from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Clinical Applications of Cardiac Bio-Markers (C-CB).
PubMed 文献 · Clin Chem Lab Med · 2025-08-12

IFCC心脏生物标志物临床应用委员会指出,现有指南推荐用利钠肽筛查糖尿病患者早期心衰,但未充分考虑检测方法间的分析差异及高生物学与 Analytical 变异性。该共识教育文件旨在描述这些困难并界定需补充数据的领域。

要点

  • 利钠肽检测方法间存在显著分析差异,解读数值需谨慎。
  • 利钠肽生物学变异高,性别、种族及临床治疗因素均影响结果。
  • 现有筛查建议未充分纳入检测变异,可能导致部分人群过度检测或劣势。

核心结论

  • 现有指南推荐用利钠肽筛查糖尿病患者心衰风险,但未充分考虑到检测方法间的分析差异及高变异性,可能影响结果解读与临床决策。

研究设计与样本

  • 国际临床化学与检验医学联合会(IFCC)心脏生物标志物临床应用委员会(C-CB)发布的共识教育文件,基于对现有指南和试验数据的评述。

主要发现

  • 指南未充分说明利钠肽检测方法间的显著分析差异及其高生物学和分析变异性。
  • 缺乏额外数据与指导时,现有建议可能导致某些群体过度检测,而另一些群体处于劣势。
  • 检测相关问题可导致利钠肽数值解读困难。

临床怎么用

  • 临床医生应了解利钠肽检测方法间的差异及数值的高变异性。
  • 解读利钠肽结果时需考虑性别、种族差异及多种临床和治疗变量。

局限性

  • 该文件为共识教育文件,指出现有数据不足的领域,未提供新的阈值或推荐剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several guidelines groups have made recommendations about how to use natriuretic peptides (NPs) to screen patients with diabetes for incipient heart failure. This group is at risk for undetected and stage B heart failure, where structural heart disease is present despite the absence of clinical signs and symptoms. These recommendations are based on trial data that suggest there are therapeutic options to benefit these patients. CONTENT: These guidelines do not adequately account for the marked analytic differences between NP assays nor their high degree of biological and analytical variability. Thus, without additional data and guidance, these recommendations could lead to excessive testing for some groups but might disadvantage others. In addition, these issues could lead to difficulties in the interpretation of values. Accordingly, the Committee on Clinical Applications of Cardiac Bio Markers of the International Federation of Clinical Chemistry has developed a consensus educational document to describe these difficulties and define areas where additional data are needed. Clinicians should be cognizant of differences in the assays for NPs, the high degree of variability of values, differences in sex and ethnicity and the need to factor in a variety of clinical and treatment variables in interpreting NP values. SUMMARY: These suggestions for diabetes eventually will include others at high risk. They will require close attention to the issues involved in measuring and interpreting NP values.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Jaffe AS, Sandoval Y, Mills NL, et al. Challenges of using natriuretic peptides to screen for the risk of developing heart failure in patients with diabetes: a report from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Clinical Applications of Cardiac Bio-Markers (C-CB). Clin Chem Lab Med. 2025. PMID: 40788396. doi:10.1515/cclm-2025-0863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。